Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grafalon for Early Borderline Lesions in Kidney Transplant Patients
NCT04936282Phase 4Active, not recruiting
- Sponsor
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of antithymocyte globulin rabbit in kidney transplant rejection, sponsored by Fundación Canaria Instituto de Investigación Sanitaria de Canarias. Started Jul 2022; status: active, not recruiting.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04936282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936282.